What is the recommended checklist before initiating hormone replacement therapy (HRT) in a perimenopausal woman?

Pre-HRT Checklist for Perimenopause

Before prescribing HRT for perimenopausal women, conduct a shared decision-making discussion that assesses individual cardiovascular and breast cancer risk factors, confirms symptom severity warrants treatment, and screens for absolute contraindications including active VTE, uncontrolled hypertension, history of estrogen-receptor-positive breast cancer, and unexplained vaginal bleeding 1, 2, 3.

Essential Clinical Assessment

Risk Stratification Components

Cardiovascular Risk Assessment:

• Measure blood pressure to identify hypertension 2
• Obtain lipid profile (total cholesterol, LDL, HDL, triglycerides) 1, 4
• Document smoking status 1
• Calculate time since menopause onset (critical for timing considerations) 3
• Assess for history of CHD, stroke, or peripheral vascular disease 1

Thromboembolism Risk:

• Screen for personal or family history of VTE 2
• If positive VTE history or known thrombophilia, refer to coagulation specialist before initiating HRT 2
• Assess obesity/BMI (obesity increases VTE risk) 2
• Document migraine with aura status (increases stroke risk) 2

Cancer Screening:

• Perform or ensure recent mammography to exclude breast malignancy 1, 5
• Document personal or family history of breast cancer 1
• For women with intact uterus: assess for unexplained vaginal bleeding requiring investigation 3
• Cervical cancer screening per standard guidelines 1

Uterine Status Determination

This is critical as it determines regimen selection:

• Women with intact uterus require estrogen PLUS progestogen to prevent endometrial hyperplasia 2, 3
• Women post-hysterectomy receive estrogen-only therapy 1

Laboratory Testing

Confirm menopausal status (if unclear):

• FSH level (elevated in menopause) 5
• Estradiol level (low in menopause) 5

Note: Single hormone measurements have limited value due to cyclic fluctuations in perimenopause 6. Clinical symptoms combined with age are often sufficient for diagnosis.

Baseline metabolic assessment:

• Lipid panel 1, 6
• Consider inflammatory markers (CRP) for high-risk patients 6

Critical Timing Considerations

The "timing hypothesis" is essential: HRT initiated within 10 years of menopause onset or before age 60 has a more favorable risk-benefit profile than therapy started later 3. Women in their 50s have different risk profiles than those in their 60s-70s (as studied in WHI) 1.

Absolute Contraindications to Screen For

• Active or history of estrogen-receptor-positive breast cancer 2, 7
• Active VTE or history without specialist clearance 2
• Active liver disease 3
• Unexplained vaginal bleeding 3
• Known or suspected pregnancy 3

Relative Contraindications Requiring Specialist Input

• History of receptor-negative breast cancer (case-by-case oncology consultation) 2
• Known thrombophilia (hematology consultation) 2
• Migraine with aura (consider transdermal route if proceeding) 2
• Uncontrolled hypertension (optimize first; transdermal preferred if proceeding) 2

Risk Communication Framework

Inform patients of the following time-dependent risks:

Early risks (first 1-2 years):

• VTE risk increases (RR ~2.0 for combined therapy) 1
• CHD and stroke risk may increase early 1

Long-term risks (with prolonged use):

• Breast cancer risk increases with combined estrogen-progestin therapy after ~3-5 years (RR 1.27) 1
• Estrogen-only therapy shows no increased breast cancer risk or possible reduction 1

Benefits to discuss:

• Most effective treatment for vasomotor symptoms 3
• Reduces fracture risk (RR ~0.75) 1
• May reduce colorectal cancer risk 1

Route Selection Based on Risk Profile

Transdermal estradiol is preferred for:

• Obesity 2
• Hypertension 2
• Migraine with aura 2
• High VTE risk 2
• Elevated cardiovascular risk 2

Oral therapy acceptable for:

• Low-risk women without above conditions 3

Documentation Requirements

Document the following in the medical record:

• Symptom severity and impact on quality of life
• Individual risk factor assessment
• Discussion of risks vs benefits specific to patient's profile
• Patient's informed preference after counseling
• Rationale for chosen regimen (estrogen type, dose, route, with/without progestogen)
• Plan for lowest effective dose and duration 1

Common Pitfalls to Avoid

Do not prescribe HRT for chronic disease prevention alone (osteoporosis, cardiovascular disease) without menopausal symptoms—risks outweigh benefits for this indication 1, 4. The evidence from USPSTF guidelines is clear that HRT should not be used routinely for preventing chronic conditions 1, 4.

Do not assume all HRT formulations have identical risk profiles. Most safety data comes from oral conjugated equine estrogen with medroxyprogesterone acetate 1. Transdermal estradiol with micronized progesterone may have different risk profiles, though definitive comparative data are limited 2.

Do not forget that women with premature ovarian insufficiency (POI, menopause <40 years) have different risk-benefit calculations and generally should receive HRT until natural menopause age (~51 years) to prevent long-term health consequences 2.